Biotechnology News and Research

RSS

Silence Therapeutics extends ongoing research, development collaboration with AstraZeneca

Silence Therapeutics plc is pleased to announce a one-year extension of its ongoing research and development collaboration with AstraZeneca. Under the terms of the agreement, which has progressed well since being signed in July 2007, Silence and AstraZeneca are jointly collaborating in the identification and optimization of five novel siRNA therapeutic molecules addressing respiratory and oncology indications.

14 Jul 2010

Improved delivery methods needed to advance gene therapy strategies for prostate cancer: Review

Improved delivery methods and better testing systems are needed to advance promising gene therapy strategies for treating prostate cancer, according to a series of review articles in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.

14 Jul 2010

OSI Pharmaceuticals terminates Offer to Purchase 2% Convertible Senior Subordinated Notes due 2025

OSI Pharmaceuticals, Inc. announced today that all of its 2% Convertible Senior Subordinated Notes due 2025 have been surrendered for conversion, as provided for in the Indenture governing the notes. As a result, no 2% Notes remain outstanding and the Company has terminated the Offer to Purchase the 2% Notes that the Company was required to make pursuant to Section 3.9 of the Indenture.

14 Jul 2010

Antigen Express granted patent for AE37 immunotherapeutic vaccine: Generex Biotechnology

Generex Biotechnology Corporation today announced that its wholly-owned subsidiary, Antigen Express, Inc., has been granted a United States patent on AE37, its lead immunotherapeutic vaccine. While Antigen Express has a strong intellectual property foundation on all Ii-Key technology, this is the first "composition of matter" patent to be issued relating to one of their development products.

14 Jul 2010

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

Protalix BioTherapeutics, Inc. announced today that the French regulatory authority has granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.

13 Jul 2010

New approach in treating heart attack, cardiomyopathy using stem cells

Presenting at the UK National Stem Cell Network annual science conference today (13 July), Professor Michael Schneider describes a new approach to treating heart attack and cardiomyopathy using stem cells.

13 Jul 2010

QIAGEN's digene HPV Test improves cervical cancer control: Study

A study released today "online first" in Cancer Causes & Control demonstrates that human papillomavirus testing, using QIAGEN's digene HPV Test, improved cervical cancer control compared to routine Pap (cytology) testing among 50,000 women across Mexico, the first country in Latin America to implement a national screening program for the high-risk types of HPV that can cause cervical cancer.

From QIAGEN Manchester Limited 13 Jul 2010

Sheffield Bio-Science honored with 2010 Lilly Global Supplier Award

Sheffield Bio-Science, a leading global pharmaceutical supplier of superior quality cell nutrition and excipient products for the biotech and pharmaceutical markets, has been awarded the distinguished 2010 Lilly Global Supplier Award.

13 Jul 2010

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.

13 Jul 2010

Food portion control is a matter of perception, suggests study

Research to be presented at the Annual Meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, suggests that the key to losing weight could lie in manipulating our beliefs about how filling we think food will be before we eat it, suggesting that portion control is all a matter of perception.

13 Jul 2010

Vivakor expands distribution channels of VivaThermic vials

Vivakor, Inc. announced that it has expanded United States distribution of its VivaThermic vials. A listing of Authorized Distributors of VivaThermic vials is available at www.vivathermic.com/distributors.

13 Jul 2010

Preclinical results of TH-302 presented at AACR Translational Cancer Medicine Meeting

Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.

13 Jul 2010

Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

Human Genome Sciences, Inc. and Lonza today announced an agreement for the future commercial supply of BENLYSTA® (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE). BENLYSTA is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in 2006.

13 Jul 2010

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests.

13 Jul 2010

Jellyfish protein may help cognitive function in Alzheimer’s

Quincy Bioscience, a research-based biotechnology company, is attending the annual Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD) sharing promising interim data from the Madison Memory Study, a randomized controlled trial, which shows the jellyfish protein apoaequorin improves cognitive function in individuals with memory concerns.

13 Jul 2010

Portion control all a matter of perception!

The key to losing weight could lie in manipulating our beliefs about how filling we think food will be before we eat it, suggesting that portion control is all a matter of perception.

13 Jul 2010

BioMimetic announces common stock public offering

BioMimetic Therapeutics, Inc. announced today a public offering of 5,000,000 shares of its common stock. BioMimetic has granted the underwriters an option to purchase up to an additional 15% of shares of common stock to cover over-allotments. BioMimetic expects to use the net proceeds of the offering for development and commercialization of its product pipeline and general corporate purposes.

13 Jul 2010

Affygility Solutions releases new version of Affytrac EH&S software with multi-corrective action functionality

Affygility Solutions, LLC, a global leader in providing environmental, health and safety solutions to the life sciences industry, announced today the launch of its newest version of its environmental, health, and safety software, Affytrac, with multi-corrective action functionality. Users can now create an infinite amount of corrective actions for a single parent issue.

13 Jul 2010

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).

12 Jul 2010

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.

12 Jul 2010

Biotechnology News and Research

Silence Therapeutics extends ongoing research, development collaboration with AstraZeneca

Improved delivery methods needed to advance gene therapy strategies for prostate cancer: Review

OSI Pharmaceuticals terminates Offer to Purchase 2% Convertible Senior Subordinated Notes due 2025

Antigen Express granted patent for AE37 immunotherapeutic vaccine: Generex Biotechnology

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

New approach in treating heart attack, cardiomyopathy using stem cells

QIAGEN's digene HPV Test improves cervical cancer control: Study

Sheffield Bio-Science honored with 2010 Lilly Global Supplier Award

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

Food portion control is a matter of perception, suggests study

Vivakor expands distribution channels of VivaThermic vials

Preclinical results of TH-302 presented at AACR Translational Cancer Medicine Meeting

Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

Jellyfish protein may help cognitive function in Alzheimer’s

Portion control all a matter of perception!

BioMimetic announces common stock public offering

Affygility Solutions releases new version of Affytrac EH&S software with multi-corrective action functionality

Rohto launches AFC Medirepair with Signum's compound Arazine in Japan

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News